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ABSTRACT: Carotid-femoral pulse wave velocity (PWV) is a gold standard non-invasive marker of arterial stiffness, but its clinical utility has been limited due to the need for normative and reference group data for specific measurement devices. Our community-based
sample (N = 502) ranged in age from 40 to 93 years after exclusion of individuals with a history of acute stroke, probable dementia,
and diabetes. PWV was assessed with the SphygmoCor® system. Means, medians, SD and 95th percentile values were presented in
ten-year age groups for normotensive and hypertensive participants. From among multiple cardiovascular risk factors, a parsimonious regression equation for predicting PWV was developed. Results were compared with the Reference Values for Arterial Stiffness
Collaboration (RVASC) study featuring mathematically standardized reference values for an aggregate of clinic sites and measurement devices. As in the RVASC study, a systematic rise in PWV with age was observed with a more pronounced rise for hypertensive
individuals, but our specific point estimates of PWV differed from theirs. Our regression models accounted for 48 percent of the variance in PWV using variables routinely available to practicing physicians: age, hypertension status, height, weight, heart rate, mean
arterial pressure, creatinine, and glucose. It is important to make available PWV norms and reference group data for specific measurement devices. Development of reference group data for smaller samples is feasible and prediction equations for PWV can be developed from diagnostic information readily available to the practicing physician.
KEYWORDS: pulse wave velocity, norms, reference values, risk factors, atherosclerosis

C

arotid-femoral pulse wave velocity (PWV) is a gold
standard non-invasive marker of arterial stiffness and
is itself a predictor of cardiovascular morbidity and
mortality *1-11+. The clinical utility of PWV has been
restricted by limited normative and reference group data, a situation exacerbated by differences in PWV measurement methods
across studies *1-14+. The continuing need for normative and reference values for specific devices has been emphasized in studies
comparing PWV measuring devices and meta-analyses *12-14+.
There are norms and reference group data for study participants in
good health by age and by combined hypertensive-diabetic status
*12-19+, but to our knowledge, none exists for hypertensive (HT)
and normotensive (NT) classifications by decades or HT and NT
groups, except for the Reference Values for Arterial Stiffness Collaboration (RVASC) study *20+. In the RVASC study, PWV data were
gathered from 13 centers across eight European countries. Sub-
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jects were classified as follows: optimal, normal, high normal,
grade I, and grade II/III hypertensive blood pressure (BP) categories by age decades, including two additional groups not by decade
but above 70 and below 30 years of age. Results for five PWV
measuring systems were combined, necessitating the merging of
findings from centers using different algorithms and different estimates of path length. Consequently, mathematical adjustments
designed to equate transit time and path length estimates across
studies were required. The RVASC (20) investigators caution readers that “Even after full adjustment, differences between algorithm
and path length were blunted, but not totally abolished.” Moreover, they point out that there was a strong data collection center
effect that was not accounted for by their standardization procedures.
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Thus, our goals were: first, provide normative and reference
group data based on a single algorithm (intersecting tangent) employed in a single widely used system (SphygmoCor®); second, to
compare our findings with those of the RVASC study in so far as
possible, e.g. we present data for persons 80 to 93 years of age
rather than combining groups above 70 years of age; and third, to
determine a parsimonious regression model for predicting PWV
beyond age, hypertension, and necessary control variables such as
height and weight, heart rate and mean arterial pressure (MAP).
Previous studies have explored relations between cardiovascular
risk factors other than hypertension and age that predict PWV *68+. Here, we are concerned with the best prediction possible from
the fewest variables beyond essential controls.

anti-diabetic agents, or by a fasting glucose level ≥ 7 mmol/l. MAP
was calculated as diastolic BP+1/3 (systolic BP – diastolic BP). The
demographic and cardiovascular morbidity characteristics of the
sample are presented in Table 1 .

METHODS

Brachial artery pressures were measured using a Critikon Dinamap ProCare 100 (oscillometric method) instrument. All precautions, training and procedures in BP measurement recommended
by the Committee Report: Blood Pressure Publication Guidelines
were observed *26+.

Participants
The PWV data were obtained from a community-based sample
of 626 participants (61% women; 14% African American) ranging in
age from 24 to 93 years (mean age 64.3). They were participants in
PWV studies conducted for the first time in the seventh wave
(repeated serial data collection) of the Maine Syracuse Longitudinal Study (MSLS), which was initiated in 1975. Recruitment procedures have been described previously *21-23+. Subjects were recruited from the Syracuse, New York community and the surrounding area by means of multi-media advertisement for participation
in a study of cognition and BP, and admitted to the study unless
they were diagnosed as psychotic or alcoholic, or were receiving
treatment for these diseases. Upon diagnosis of hypertension at
any wave, individuals were referred to their physician for treatment and 88.6 percent were treated at wave 7.
Carotid-femoral PWV (m/s) was measured for the first time at
the seventh (final) wave (2006-2009) of the MSLS and cardiovascular disease (CVD) risk factor covariates from that wave were employed. Thus the present data analysis is cross-sectional. In an
initial analysis of the 626 participants for whom PWV data were
obtained, subjects were excluded in the following sequence: (1)
dementia (n=2); (2) history of acute stroke (n=14); (3) diabetes (n=
93); and (4) under 40 years of age (n=15). Individuals under 40
years of age were excluded due to the small number of subjects in
that range. The final dementia-free sample consisted of 502 individuals. Cardiovascular risk factor and demographic data were
available for an additional 174 persons meeting these criteria but
missing PWV data. Their PWV values were derived by multiple
imputations *24+, thus increasing the sample size to 676 for a secondary set of analyses.
The clinical diagnosis of dementia was determined from cognitive data and family informant-report, medical records or chart
review *21-23+ using the National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria *25+. Prevalent stroke, defined as a focal neurological deficit of acute onset
persisting more than 24 hours, was based on self-report and record review, confirmed by hospitalization, treatment for stroke, or
both. Diabetes mellitus was defined by treatment with insulin, oral
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Procedure
The University of Maine approved this investigation and informed consent for data collection was obtained from all participants. Participants were admitted to the study center on the day
of the study, followed by medical history interview and then PWV
measurements.
Blood Pressure (BP) and Pulse Wave Assessment

Following 10 minutes of supine rest, 15 consecutive automated
brachial BP measurements were taken at 1 minute intervals, 5
supine, 5 standing, and 5 sitting. The resulting 15 measurements
were averaged and used for analyses outlined below. After an
additional 10 minutes rest, five supine brachial artery BP measurements were obtained, averaged and used for calibration of the
SphygmoCor® device *27+. This procedure permitted us to maintain
the BP measurement protocol that has been used since the since
the beginning of the MSLS study and to obtain additional supine
measurements for device calibration purposes.
PWV was assessed noninvasively using the SphygmoCor® system. Electrocardiogram-gated carotid and femoral waveforms
were recorded using applanation tonometry. Carotid-femoral path
length was measured as the difference between the surface distances joining (1) the suprasternal notch, the umbilicus and the
femoral pulse and (2) the suprasternal notch and the carotid pulse.
Carotid-femoral transit time was estimated in 8-10 sequential femoral and carotid waveforms as the average time difference between the onset of the femoral and carotid waveforms. The foot of
the pulse wave was identified using the intersecting tangent method. PWV was calculated as the carotid-femoral path length divided
by the carotid-femoral transit time *27-28+. This is an established,
non-invasive and reproducible method to determine arterial stiffness *10, 27-28+ and no adjustments are required for transit time
and path length *29, 30+.
Predictors and Covariables
Hypertension was defined as taking anti-hypertensive medications at wave 7 or exhibiting an average (over 15 measurements)
brachial artery systolic and diastolic BP equal to or greater than
140/90 mmHg. The methods used to assess CVD risk variables and
other covariates at wave 7 have been presented in detail previously *21-23+.
Two major diagnostic groups were employed: (1) a NT group (n=
206); and (2) a HT group (n= 296) using major selection criteria
employed in the RVASC study (20) but with the inclusion of treated
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Table 1. Sample characteristics by diagnostic category.
Normotensive
n= 206

Hypertensive
N= 296

Age (years)

61.0 (11.7)

67.4 (11.3)

<0.001

PWV (m/s)

8.9 (2.0)

11.0 (2.9)

<0.001

BMI (kg/m2)

27.1 (5.1)

30.4 (6.2)

<0.001

Waist (cm)

86.4 (15.2)

96.5 (13.9)

<0.001

116.6 (12.3)

137.4 (20.0)

<0.001

73.2 (7.8)

79.9 (10.4)

<0.001

43.3 (10.0)

57.5 (16.4)

<0.001

87.7 (8.3)

99.1 (12.1)

<0.001

HR (beats/min)

57.7 (7.9)

60.3 (9.6)

0.002

Glucose (mg/dl)

88.6 (9.2)

94.6 (11.0)

<0.001

Creatinine (mg/dl)

1.0 (0.2)

1.1 (0.2)

0.006

Cholesterol (mg/dl)

200.3 (37.4)

185.0 (39.2)

<0.001

HDL (mg/dl)

58.8 (16.4)

51.7 (14.6)

<0.001

LDL (mg/dl)

122.4 (31.1)

109.7 (33.2)

<0.001

Triglycerides (mg/dl)

97.3 (67.8)

117.5 (58.4)

<0.001

Total/HDL

3.6 (1.0)

3.8 (0.9)

0.10

Alcohol (oz/wk)

1.4 (2.4)

1.5 (2.6)

0.59

Cigarettes/wk

7.6 (38.3)

8.5 (34.1)

0.79

Height (cm)

166.2 (9.2)

167.9 (10.5)

0.06

Weight (kg)

75.0 (16.4)

85.6 (18.9)

<0.001

Homocysteine (μmol/l)

9.1 (2.1)

10.8 (3.6)

<0.001

SBP (mmHg)1
DBP (mmHg)

1

PP (mmHg)1
MAP (mmHg)

1

Duration of hypertension

16.1 (14.3)

Education (years)2

15.3 (2.7)

14.4 (2.7)

<0.001

% Women

70.9

58.5

0.004

% Anti-hypert Meds
% CVD

2

85.8
0.5

13.9

<0.001

% African American

9.2

12.2

0.30

% APOE-ε4

29.0

29.9

0.08

1

brachial pressure

2

CVD: cardiovascular disease (includes myocardial infarction, coronary artery disease, and heart failure)

Note: a t-test was used for continuous variables; a chi-square test was used for categorical variables *28+.
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HT individuals so as to achieve maximum cell size for cross tabulation of age and HT groups. Methods for adjusting for treatment are
defined in the results section.
Statistical Analysis Plan
SAS version 9.2 and Stata 11 were used for all analyses. The following steps were employed: (1) description of, and statistical
comparisons between, demographic and clinical parameters of the
NT and HT groups; (2) multiple imputation of missing PWV values;
(3) presentation of descriptive reference group data by age and BP
classifications; and (4) multiple regression analyses with two purposes, (a) determine the statistical significance of age effects, HT
group effects, and their interactions, and (b) determination of the
increased prediction of PWV afforded by adding other CVD risk
factors to the PWV equation involving age and HT parameters.
Because of the positively skewed nature of the PWV values,
sensitivity analyses were performed including analysis of log PWV,
robust regression and examination of residuals and influence statistics. Diagnostic results were within acceptable values and revealed no issues. The pattern of results was identical for log PWV
and raw score data and results are reported for raw scores which
are most directly interpretable.

dition of 10 and 5 mmHg constants used in other studies *33-34+.
Consequently, we utilized the 8 and 4 mmHg adjustment for all BP
classifications and calculation of MAP. To check on the effectiveness of the adjustment we compared treated and untreated HT
individuals with respect to PWV values after our adjustments for
treatment and found no statistically significant effects of treatment
(p= 0.93).
MSLS Classifications
Figure 1 shows a systematic rise in PWV with age and consistently higher PWV values for the HT group. The top and bottom
portions of Table 2 show, respectively, reference group data samples based on the observed and imputed PWV values. Both show
the RVASC PWV data where comparisons are possible due to reporting of data for the same age groups. PWV values were higher
for the HT participants, and increased with age within the NT and
HT categories, and at each age the HT cohort exhibited higher PWV
values. This same pattern was seen for medians and for the 95 th
percentile of the distribution. Regardless of whether observed or
imputed means are employed in the analysis, agreement with the
RVASC study is generally good. Mean values for the RVASC study
are within one-half SD from the MSLS means.

Using available CVD covariables and demographics, the imputation procedure used chained equations to construct 10 imputed
data sets designed to provide the missing PWV data. Results from
analyses were combined across imputations using Rubin’s rules
*31+. Agreement obtained with imputation and listwise deletion
was high and the similarity of the pattern of significant results for
the observed PWV and the imputed + observed values was high as
discussed below. This allowed us to determine the impact of missing data on our findings and increase our sample size for a secondary presentation of the normative and reference value data. Missing data fractions were within statistically acceptable limits.
RESULTS
Sample Characteristics
Table 1 shows the demographic and cardiovascular risk factors
for HT and NT groups for the observed data and p-values for differences among the groups. For most of the variables presented,
compared to the NT cohort, persons in the HT cohort exhibited a
higher prevalence of CVD risk factors or higher clinical values
(p<0.05), were older (p< 0.05) and somewhat less educated
(p<0.05), although education differences were slight in absolute
terms.

Figure 1. A bar plot showing trends for age within HT and NT
groups.
The regression equation for the categorical regression with age
centered was as follows: PWV = 9.152 + 0.844 × age group + 1.479
× HT + 0.453 × age group × HT; R2 = 0.36. The age group (p< 0.001),
HT (p<0.001) and the age group x HT (p<0.01) effects were all statistically significant.

Preliminary Adjustment

More Refined Diagnostic Groups

A majority of HT participants were treated by wave 7. In order to
compare our data with RVASC data for subcategories of HT it was
necessary to estimate untreated BP values. Following Tobin et al.,
we added a “reasonable constant” to systolic and diastolic BP for
treated HT individuals *32+. With age and BMI controlled, differences between treated and untreated systolic and diastolic values
in our study were 8 and 4 mmHg respectively. These values were
used as constants. Results were essentially the same with the ad-

Visual inspection indicates a high agreement between imputed
and observed values of PWV. Consequently, using the imputed
data we were able to achieve cell sizes sufficient to reproduce reference group data for some more specific diagnostic categories
employed in RVASC and defined in Table 3. We show difference
scores for PWV values for RVASC and our study. While sample size
is quite low at younger ages for our cells representing the RVASC
hypertension grade II/III categories, the progression of increased
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112
112
77

60-69

70-79

80-93

24

80-93

50-59

54

70-79

24

62

60-69

40-49

90

50-59

Hypertensive

42

40-49

Normotensive

47

80-93

N

84

70-79

Age Group

85

60-69

Group/Imputed

63

15

80-93

50-59

40

70-79

17

48

60-69

40-49

69

50-59

Hypertensive

34

40-49

Normotensive

N

Age Group

Group/Observed

13.2

12.2

10.4

9.4

8.7

11.5

10.3

8.9

8.1

8.1

Mean

13.1

12.3

10.3

9.3

8.6

11.4

10.1

8.9

8.0

8.1

Mean

2.5

2.7

2.1

1.4

1.4

2.1

1.9

1.7

1.2

1.3

SD

3.1

3.1

2.3

1.5

1.5

2.6

2.1

1.9

1.3

1.3

SD

13.4

11.9

10.4

9.4

8.4

11.0

10.4

8.7

8.0

7.9

Median

12.6

11.7

9.9

9.3

8.2

10.5

10.0

8.5

7.9

7.8

Median

Table 2. Normative and reference group data for PWV by hypertensive status and age group.

18.0

18.1

14.2

11.7

11.4

15.6

14.0

11.8

10.6

10.4

95th

18.5

18.5

14.2

11.7

11.8

17.1

14.6

12.1

10.6

10.4

95th

11.4

9.6

9.0

9.7

8.2

7.4

RVASC M

11.4

9.6

9.0

9.7

8.2

7.4

RVASC M

-1.00

-0.2

-0.3

-0.8

-0.1

0.7

MSLS-RVASC

-1.1

-0.3

0.4

-0.8

-0.2

0.7

MSLS-RVASC
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-1.3
-0.9
2.8
2.3
10.9
13.1
13
43
-0.7
-0.4
2.0
2.7
10.4
12.5

Grade II/III HT: ≥160/100 mmHg

4

Grade I HT: ≥140/90 mmHg and <160/100 mmHg

Normal: ≥120/80 mmHg and <140/90 mmHg

3

Optimal: <120/80 mmHg

2

1

1.6
2.3
10.2
11.0
23
38
-1.0
0.1
1.1
1.7
8.1
10.3

Note: High normal and normal groups were combined to increase sample size.

99
146
0.2
-0.8

SD
1.3
1.2
SD
1.4
1.4
M
8.6
9.3
N
19
73
MSLSRVASC
0.9
-0.1
SD
1.3
1.2
N
20
31

M
8.6
8.5

Normal

MSLSRVASC
0.7
0.3
SD
1.2
1.2
M
7.7
7.9
N
22
59

39
40
60-69
70+

Means for PWV for men and women were 10.7 and 9.8 m/s
respectively (p< 0.001). Preliminary analyses indicated the absence of a quadratic effect for age, and sex did not interact signifi-

40-49
50-59

Men Versus Women

Age
Group

Next we determined how well the RVASC equations predicted
PWV data obtained in the MSLS. Applying the RVASC equations,
RVASC-Table 6 top *20+, to the observed data obtained in the
MSLS, we calculated Ŷ PWV for each subject as a function of HT or
age. These equations accounted for 36 percent variance in our
PWV values (R2= 0.36; p <0.001).

Optimal

Using only the observed data for the expanded regression analysis (Table 3 top), the regression equation was as follows: PWV =
10.059 + 1.069 × age group + 0.447 × BP diagnostic category +
0.081 × age group × BP. Significant age group (p<0.001) and BP
diagnostic group (p< 0.001) group interactions were observed and
the age group x BP diagnostic group interaction p value was 0.06;
R2= 0.38.

2

RVASC investigators make a distinction between normal PWV
values and reference group values. This is possible in the present
study if we use the optimal or normal BP groups, or both as normative (in the sense of normal) groups. There was only one NT
individual with CVD (diagnosed coronary artery disease in the 60
to 69 year-old normal BP diagnostic group). Removing that individual made no difference in results obtained for this group for either
the observed or imputed data. As an option to the normal BP
group as a basis for “normal BP” values one may use the optimal
BP diagnostic group (Table 3).

1

Norms versus Reference Values

Table 3. Mean imputed PWV (m/s) values by blood pressure category and age group.

Figure 2. A bar plot showing trends for age within BP categories.

Blood Pressure Category
Grade I HT3

MSLSRVASC
0.0
-0.3

N
5
6

M
8.9
9.9

Grade II/III HT4

PWV across age and HT groups is consistent with expectations.
Deviations of RVASC mean PWV values from MSLS mean PWV
values are within 1 SD or less of the SD values reported for MSLS.
The trend across BP groups and age is illustrated in Figure 2.

MSLSRVASC
-0.9
-0.6
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cantly with age or HT groups (all p values> 0.14). With adjustment
of the full model (discussed below), the least-square means for
men and women were 10.2 and 10.0 m/s respectively (p= 0.41).
Expanded Models with Risk Factors
Figure 3 presents a scatter plot and regression lines (slopes) for
the observed data with age as a continuously distributed variable.
The final steps in our analyses were designed to identify a parsimonious regression model that would increase the prediction of PWV
beyond that possible with age and HT parameters alone. The first
set of variables, considered essential controls *15-21+, were fixed in
the model: Age + HT + (HT × Age) + Height + Weight + Heart Rate +
MAP + Lipid Lowering Drugs (1 = drug). Anti-hypertensive treatment effects were not significant and not included in the model.
Once fixed variables were entered into the equation, candidate
variables (footnote, Table 4) were entered with a stepwise backward elimination procedure. Variables that did not enter the equation significantly (p< 0.10) via the backward elimination procedure
were not included in the final equation.

-significant associations were excluded. A regression table based
on the imputed data is not shown as the same pattern of significant associations and R2 values was obtained. Similarity of results
obtained for observed and imputed values was confirmed by a
Wald test of equality of coefficients between the least squares
deletion model (observed values) and the multiple imputation
model: F(10,594)= 0.05, p> .999.
Final Analyses
African American versus other ethnic group status did not enter
into the regression equation significantly (p= 0.19) and the pattern
of results was not affected by excluding African Americans from
the sample.
The CVD variable could not be adjusted statistically because of
its very low prevalence in the NT groups. However, when persons
with CVD (see Table 1) were excluded from the analyses, the
pattern of results was nearly identical to those presented above.
DISCUSSION
We provide PWV normative and reference group data by NT and
HT groups for the SphygmoCor® device, a system that uses an intersecting target algorithm, a function shared with numerous other
systems *13+. The rise in PWV with age and hypertension, and the
interaction between hypertension and age is consistent with the
RVASC *20+ study and others. Our data clearly indicate the limitations with respect to a focus on a single clinically significant fixed
threshold value for elevated PWV, e.g., 12 m/s as has been recommended *9+. In our community-based study only for the 70 to 79
year old HT group do we see mean PWV values at the recommended 12 m/s threshold value. Mean and median values for younger
subjects (60 to 69, or younger), HT or NT, fall below this threshold.
For the classification based on more refined diagnostic groups (see
Table 3), only the mean values for 70+ year old, Grade I and Grade
II/III HT individuals were at or above the 12 m/s threshold.

Figure 3. Association between age and PWV for the hypertensive (dots, solid line) and normotensive (circles, dashed line)
groups. The regression equation for age and hypertension for
the overall sample (with age centered) was: PWV = 9.210 +
0.089 × age + 1.437 × hypertension + 0.041 × age × hypertension; R2 = 0.36.
As may be seen in Table 4, also for the observed data, the basic
age + HT + (HT × Age) model accounted for 36 percent of the variance in PWV; the final model, each variable adjusted for all others,
accounted for 47 percent. Of all the candidate variables, only creatinine and glucose entered the equation significantly with alpha =
0.10, and account for a small portion of variance, ΔR2= 0.024. The
same risk factors were significant and the regression model was
similar when the larger imputed PWV data set was employed,
when sex (p= 0.41) was included in the model, and when other non
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The validity of the RVASC regression equations using age and HT
parameters is exemplified by the fact that they account for almost
the same amount of variance (36 percent) in our own PWV values,
as do our own equations when limited to those parameters.
Moreover, the agreement between the RVASC PWV reference
values and ours is remarkably high given the difference in sample
size between the studies. This finding endorses the usefulness of
their data under circumstances where norms and reference groups
for one’s specific device and laboratory are unavailable, but does
not obviate the need for system-specific studies such as the present. Limitations elucidated by the RVASC team include two points
relevant to this issue: (1) their mathematical calculations attenuated but did not totally abolish differences in PWV on the basis of
different algorithms and methods for determining path length; and
(2) there was a strong data collection center effect for PWV that
was not accounted for by their standardization procedures.
Our third study goal was to develop a parsimonious model, using multiple risk factors that would allow a prediction of PWV beyond that afforded by age and hypertension. We found that a
group of risk factor variables readily available to most practicing
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Table 4. Raw multivariable regression coefficients (b), standard errors (SE) expressing the relationship between risk factors and PWV (m/s) with each b adjusted for all others.1,2
Covariables
Intercept
Age (years)3
Hypertension (1= yes)
Hypert × Age3
Height (cm)
Weight (kg)
Heart Rate (bpm)
MAP (mmHg)
Lipid Meds (1=yes)
Creatinine (μmol/l)2
Glucose (mmol/l)2

b
-4.772*
0.105***
0.117
0.041**
0.013
0.018**
0.039***
0.045***
-0.315
1.433**
0.034***

SE
2.061
0.013
0.258
0.017
0.011
0.007
0.011
0.009
0.209
0.532
0.009

Cumulative R2

Delta R2

0.297
0.360

0.063

0.450

0.090

0.4744

0.024

1

8 and 4 mmHg respectively are added to treated BP levels prior to analysis; the pattern of significant results is the same without adjustment. Findings are the same with waist circumference substituted for height+weight or in absence of adjustment for lipid medications.
2

Variables up to and including lipid medications were fixed in the model (could not be eliminated).
Once the fixed variables were entered into the equation, the following candidate variables were
entered into a stepwise backward elimination: education (years), plasma homocysteine (μmol/l),
cigarettes/wk (or heavy smoking, >15/day), glucose (mmol/l), creatinine (μmol/l), triglycerides
(mmol/l) (or other lipid values in separate analyses), alcohol consumption (g/wk), APOE genotype
(ε4/no ε4), race/ethnicity (African American versus other), and c-reactive protein.
3

Age is centered

4

model R2 (df = 10; 485)

*p< 0.05, **p< 0.01, ***p< 0.001

physicians (Table 4) allowed us to account for 47 percent of the
variance in PWV as opposed to the 36 percent accounted for by
the age and hypertension variables. These findings are consistent
with findings that CVD risk factors other than hypertension and
age are predictors of PWV *6-8+.

the analyses. In the Caerphilly Prospective Study *6+, glucose was
positively associated with PWV, but only at baseline. In the same
study, creatinine, an index of kidney disease, was significantly associated with PWV both at baseline and after 20 years of follow-up
*6+.

In terms of the question of which CVD risk factors are dominant
with respect to the prediction of PWV, our results are consistent
with a recent comprehensive review and meta-analysis of 65 studies *35+. The conclusion reached in this study was that the contribution of risk factors to the prediction of PWV other than age, hypertension, or BP is either small or non-significant. Viewed from a
general perspective, our findings are entirely consistent with this
conclusion. The point we wish to make in our analysis is that additional variables that account for a small percentage of variance in
PWV beyond that accounted for by age and hypertension do increase the prediction of PWV.

Study Limitations

After age + hypertension, age x hypertension interactions and
essential controls were fixed in our regression model, only glucose
and creatinine entered into the regression model significantly. It is
of interest that glucose was positively associated with PWV despite
the fact that persons with diabetes mellitus were excluded from
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As was true for the RVASC investigation, our study was limited
because PWV was not measured longitudinally. Physicians treat
age cohorts (people born at the same time) differently and thus
cross-sectional norms and reference groups are of value, but longitudinal data are necessary to answer the need for data relevant to
serial treatment of the same patients over time.
It is possible discrepancies in point estimates between RVASC
and our study related to our smaller sample, but results were the
same when imputation of missing data allowed us to increase sample size, and dissimilarity between our study and RVASC was not
systematically seen as a function of cell size in our study.
Over- or under-adjustment of BP to estimate the untreated condition may have resulted from the Tobin et al. *32+ adjustment
procedure, although the same results for various regression anal-
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yses were observed with conventional covariance analyses using
raw scores with anti-hypertensive drug treatment as a covariate.
Moreover, our adjustments with the purpose of obtaining untreated BP value estimates in those who were treated cannot explain
differences between point estimates in the RVASC and MSLS studies since those differences are there for untreated NT individuals.

4. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM,
London GM. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735-738.

We had too few participants to permit construction of normative values for African American participants. Shiburi et al. *19+
provides reference values by age for SphygmoCor® measurements
obtained in South Africans of African Ancestry. Normative values in
other cultures and minority groups need to be provided within
extensive BP classifications as well as age groups.

6. McEniery CM, Spratt M, Munnery M, Yarnell J, Lowe GD, Rumley A,
Gallacher J, Ben-Shlomo Y, Cockcroft JR, Wilkinson IB. An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the
Caerphilly prospective study. Hypertension 2010; 56:36-43

CONCLUSIONS
Reference values for clinically significant PWV values must take
age into account. There is relatively good agreement between
PWV norms and reference group values for a large aggregate sample (RVASC) using multiple instruments and the much smaller MSLS
sample, but an inexact match for within-cell PWV values confirms
the need for normative and reference group values derived in
one’s own region with one’s own measuring device. From an actuarial prospective, predicting PWV from CVD risk factors, the largest
proportion of the best predictions of PWV values may be based on
relatively few CVD risk factors readily available to most diagnostic
and treatment centers.
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